Accelerating and enabling your research interests
Partnering with Tempus provides access to an integrated multi-omic analytical platform and artificial intelligence capabilities designed to accelerate scientific discoveries.
Our solutions
Institutions can access 3.8 million de-identified patient records, proprietary technologies to explore and identify patterns in the data, and a path for collaborative research with Tempus.
Leverage the Tempus database to explore, power, and validate a hypothesis in precision oncology, aiming to produce presentations and publications.
Tempus offers a broad range of contract and traditional clinical options using our CAP-accredited CLIA-certified next-generation sequencing labs.
Tempus has additional capabilities including single-cell sequencing, genome-wide liquid biopsy profiling, spatial transcriptomics, methylation, genotyping and more.
Tempus provides high-throughput solutions that deliver comprehensive datasets for a critical, integrated, and holistic understanding of your population. We offer a broad range of technologies to support research and development, including genotyping, methylation, NGS, and proteomics.
- Genotyping — A wide portfolio of genotyping solutions to support data projects of varying sizes.
- Methylation — Epigenetic & DNA methylation profiling from one of the highest-throughput methylation labs in the US.
- NGS — The full Illumina NGS suite of instruments to support all of your sequencing needs.
- Proteomics — Leading proteomic technologies with high-throughput capabilities, enabling precise biomarker discovery and expansive multi-omic analysis.
Our comprehensive immunotherapy platform provides sophisticated specimen analysis and data products, enabling our partners to assess key aspects of the tumor microenvironment (TME) and uncover vital genomic information that can be leveraged to optimize therapy response, identify novel biomarkers, and further stratify patient populations.
- Tumor Mutational Burden (TMB)
- Microsatellite Instability (MSI) Status
- Gene Expression Target Profiling
- Neoantigen Prediction
- Human Leukocyte Antigen (HLA) Typing
- HLA Loss of Heterozygosity (LOH)
- Immune Infiltration
- And more
BIOLOGICAL MODELING
Accelerating how researchers explore, evaluate, and design cutting-edge cancer treatments
At the Tempus | M modeling lab, a state of the art in-vitro facility, we use ex vivo tumor organoid biological modeling to understand the consequence of cancer genome alterations on growth, therapeutic sensitivity, and immune evasion.
Organoid development
Using the Tempus xT assay on ex vivo tumors, Tempus correlates clinical patients’ responses with expanded real world cohorts, then further broadens these data sets with tumor organoids possessing somatic mutations or RNA expression signatures of interest to develop a model of universal concordance. Tempus organoid panels have the potential to validate hypotheses and observations from real world data; discover novel pathways and tumor drivers; and construct large scale data sets of in vitro sensitivities across hundreds of unique patients ex vivo for any given cancer, or target of interest.
Molecular Profiling
Tumor organoids are characterized by the Tempus xT 648 gene-panel and whole transcriptome analysis including copy number prediction. An informatics pipeline is used to compare mutational recapitulation between the organoid models and the originating patient’s tumor. Organoids are also annotated for genome-wide analyses such as MSI and Homologous Recombination Deficiency (HRD).
Therapeutic Profiling
Tumor organoids can be used to study established small molecules, antibody drug conjugates and effector cell systems such as CAR-T or CAR-NK. Tumor organoid response is evaluated with a robust and reproducible high content and machine learning based assay.
Trial Programs
Brings biomarker-driven clinical trials closer to patients across a just-in-time network of industry sponsors and providers with deep research expertise
Tempus generates, organizes, and analyzes extensive amounts of data to support providers in identifying relevant and actionable clinical trials for their patients. Our TIME Trial® Program enables providers in the network to have access to a portfolio of clinical trials and expand treatment options for their patients. All participants in the TIME Trial® Program utilize a pre-packaged clinical trial agreement, a pre-negotiated budget, a central IRB, and a team of dedicated Tempus research liaisons to help shorten trial start from months into weeks.
This is AI-enabled precision medicine
This is the future of healthcare.